Estimating Cost Savings from Early Cancer Diagnosis
Data 2(3) (2017) 30
22 Pages Posted: 28 May 2017 Last revised: 3 Apr 2019
Date Written: August 23, 2017
We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.
Keywords: cancer, costs, incidence, stage, early diagnosis, treatment, data
JEL Classification: I11, G00
Suggested Citation: Suggested Citation